NTCELL® CLINICAL STUDY IN PARKINSON'S MEETS ENDPOINTS

Living Cell Technologies Advancing Regenerative Cell Therapy into Larger Phase IIb Study to Evaluate Its Potential as a Disease-modifying Treatment   Company to Host Conference Call on Wednesday, June 17, at 3:30 p.m. Pacific Daylight Time   SYDNEY & AUCKLAND, New Zealand, June 15 (Bernama-BUSINESS WIRE) -- Living Cell Technologies Limited (LCT) today announced results from a Phase I/IIa clinical study of NTCELL®, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. NTCELL implantation also improved clinical features of Parkinson’s disease in the four patients studied, as measured by validated neurological rating scales and questionnaires, with the improvement sustained at 26 weeks post-implant. http://mrem.bernama.com/viewsm.php?idm=24671